2-benzyloxycarbonylmethyl-2-(pyrrol-1-yl)malonic acid diethyl ester | 147193-85-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-benzyloxycarbonylmethyl-2-(pyrrol-1-yl)malonic acid diethyl ester
• 英文别名: 2-O-benzyl 1-O,1-O-diethyl 1-pyrrol-1-ylethane-1,1,2-tricarboxylate
• CAS: 147193-85-9
• 化学式: C₂₀H₂₃NO₆
• 分子量: 373.406
• InChiKey: IKUILZQEAYQOPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  27
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  83.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-benzyloxycarbonylmethyl-2-(pyrrol-1-yl)malonic acid diethyl ester 在 palladium on activated charcoal 氨 、 氢气 、 potassium carbonate 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 丙酮 、 乙腈 为溶剂， 50.0 ℃ 、101.33 kPa 条件下， 反应 4.0h， 生成 ethyl 2,5-dioxo-3-(1H-pyrrol-1-yl)pyrrolidine-3-carboxylate
  参考文献：
  名称：

  Novel, Highly Potent Aldose Reductase Inhibitors:  (R)-(−)-2-(4-Bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine- 4-spiro-3‘-pyrrolidine-1,2‘,3,5‘-tetrone (AS-3201) and Its Congeners

  摘要：

  A series of novel tetrahydropyrrolo[1,2-a]pyrazine derivatives were synthesized and evaluated as aldose reductase inhibitors (ARIs) on the basis of their abilities to inhibit porcine lens aldose reductase (AR) in vitro and to inhibit sorbitol accumulation in the sciatic nerve of streptozotocin-induced diabetic rats in vivo. Of these compounds, spirosuccinimide-fused tetrahydropyrrolo[1,2-a]pyrazine-1,3-dione derivatives showed significantly potent AR inhibitory activity. In the in vivo activity of these derivatives, 2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo- [1,2-a][1,2a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (23t) (SX-3030) showed the best oral activity. The enantiomers of 23t were synthesized, and the biological activities were evaluated. It was found that AR inhibitory activity resides in the (-)-enantiomer 43 (AS-3201), which was 10 times more potent in inhibition of the AR (IC50 = 1.5 x 10(-8) M) and 500 times more potent in the in vivo activity (ED50 = 0.18 mg/kg/day for 5 days) than the corresponding (+)enantiomer 44 (SX-3202): From these results, AS-3201 was selected as the candidate for clinical development. The absolute configuration of AS-3201 was also established to be (R)-form by single-crystal X-ray analysis. In this article we report the preparation and structure-activity relationship (SAR) of tetrahydropyrrolopyrazine derivatives including a novel ARI, AS-3201.

  DOI：

  10.1021/jm9802968
• 作为产物：
  描述：

  2-(1H-吡咯-1-基)丙二酸二乙酯 、 2-溴乙酸苄酯 以 N-甲基乙酰胺 、 正己烷 、 乙酸乙酯 、 mineral oil 为溶剂， 以91%的产率得到2-benzyloxycarbonylmethyl-2-(pyrrol-1-yl)malonic acid diethyl ester
  参考文献：
  名称：

  Tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine derivatives,

  摘要：

  Tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine衍生物的化学式为：##STR1##其中R.sup.1和R.sup.2独立地为氢、卤素、三氟甲基、具有1至6个碳原子的烷基、具有1至6个碳原子的烷氧基或硝基，R.sup.3为氢、卤素或具有1至6个碳原子的烷基，以及其药学上可接受的盐，制备方法和含有这些化合物的药物组合物。这些化合物及其盐显示出优秀的醛糖还原酶抑制活性，可用于预防和治疗糖尿病并发症。

  公开号：

  US05258382A1

文献信息

• Tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine derivatives,
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：US05258382A1

  公开（公告）日：1993-11-02

  Tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine derivatives of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are independently hydrogen, halogen, trifluoromethyl, alkyl having 1 to 6 carbon atoms, alkoxy having 1 to 6 carbon atoms, or nitro, and R.sup.3 is hydrogen, halogen or alkyl having 1 to 6 carbon atoms, and pharmaceutically acceptable salts thereof, processes for preparation thereof, and pharmaceutical composition containing the same. Said compounds and their salts show excellent aldose reductase inhibitory activity and are useful for the prevention and treatment of diabetic complications.

  Tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine衍生物的化学式为：##STR1##其中R.sup.1和R.sup.2独立地为氢、卤素、三氟甲基、具有1至6个碳原子的烷基、具有1至6个碳原子的烷氧基或硝基，R.sup.3为氢、卤素或具有1至6个碳原子的烷基，以及其药学上可接受的盐，制备方法和含有这些化合物的药物组合物。这些化合物及其盐显示出优秀的醛糖还原酶抑制活性，可用于预防和治疗糖尿病并发症。
• Tetrahydropyrrolo 1,2-a pyrazine-4-spiro-3'-pyrrolidine derivatives, processes for the preparation thereof and pharaceutical compositions containing the same
  申请人：DAINIPPON PHARMACEUTICAL CO., LTD.

  公开号：EP0520320A2

  公开（公告）日：1992-12-30

  Tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine derivatives of the formula: wherein R¹ and R² are independently hydrogen, halogen, trifluoromethyl, alkyl having 1 to 6 carbon atoms, alkoxy having 1 to 6 carbon atoms, or nitro, and R³ is hydrogen, halogen or alkyl having 1 to 6 carbon atoms, and pharmaceutically acceptable salts thereof, processes for preparation thereof, and pharmaceutical composition containing the same. Said compounds and their salts show excellent aldose reductase inhibitory activity and are useful for the prevention and treatment of diabetic complications.

  式中的四氢吡咯并[1,2-a]吡嗪-4-螺-3'-吡咯烷衍生物： 其中R¹和R²独立地为氢、卤素、三氟甲基、具有1至6个碳原子的烷基、具有1至6个碳原子的烷氧基或硝基，R³为氢、卤素或具有1至6个碳原子的烷基，及其药学上可接受的盐、其制备工艺和含有这些物质的药物组合物。上述化合物及其盐类显示出优异的醛糖还原酶抑制活性，可用于预防和治疗糖尿病并发症。
• Tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：EP0520320B1

  公开（公告）日：1997-09-10
• US5258382A
  申请人：——

  公开号：US5258382A

  公开（公告）日：1993-11-02
• Novel, Highly Potent Aldose Reductase Inhibitors:  (<i>R</i>)-(−)-2-(4-Bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-<i>a</i>]pyrazine- 4-spiro-3‘-pyrrolidine-1,2‘,3,5‘-tetrone (AS-3201) and Its Congeners
  作者：Toshiyuki Negoro、Makoto Murata、Shozo Ueda、Buichi Fujitani、Yoshiyuki Ono、Akemi Kuromiya、Masanobu Komiya、Kenji Suzuki、Jun-ichi Matsumoto

  DOI：10.1021/jm9802968

  日期：1998.10.1

  A series of novel tetrahydropyrrolo[1,2-a]pyrazine derivatives were synthesized and evaluated as aldose reductase inhibitors (ARIs) on the basis of their abilities to inhibit porcine lens aldose reductase (AR) in vitro and to inhibit sorbitol accumulation in the sciatic nerve of streptozotocin-induced diabetic rats in vivo. Of these compounds, spirosuccinimide-fused tetrahydropyrrolo[1,2-a]pyrazine-1,3-dione derivatives showed significantly potent AR inhibitory activity. In the in vivo activity of these derivatives, 2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo- [1,2-a][1,2a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (23t) (SX-3030) showed the best oral activity. The enantiomers of 23t were synthesized, and the biological activities were evaluated. It was found that AR inhibitory activity resides in the (-)-enantiomer 43 (AS-3201), which was 10 times more potent in inhibition of the AR (IC50 = 1.5 x 10(-8) M) and 500 times more potent in the in vivo activity (ED50 = 0.18 mg/kg/day for 5 days) than the corresponding (+)enantiomer 44 (SX-3202): From these results, AS-3201 was selected as the candidate for clinical development. The absolute configuration of AS-3201 was also established to be (R)-form by single-crystal X-ray analysis. In this article we report the preparation and structure-activity relationship (SAR) of tetrahydropyrrolopyrazine derivatives including a novel ARI, AS-3201.